A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: The University of Queensland
A team of Australian scientists has developed cyborg cockroaches for medical missions. Researchers from the University of Queensland fitted Giant Burrowing Cockroaches with a removable navigation system that enables them to be remotely piloted through complex terrain and rubble.
The cockroaches are equipped with cameras and miniature medical injectors to deliver supervised emergency care to people trapped in collapsed buildings or caves.
Called ‘Paraborgs’, the cyborg insects go beyond searching for survivors to actively assisting them. In the paper, published in Advanced Science, the researchers said the long-term vision is to deploy swarms of specialized cyborg insects at disaster sites, with each performing a complementary role.
“The vision is not to replace first responders, but to give them another way to see, reach and potentially help people when direct access is impossible,” said Dr Vo-Doan from the UQ Biorobotics Lab.
Director of the UNSW Medical Robotics Lab Associate Professor Thanh Nho Do said the Paraborg technology could extend the reach of emergency medicine.
“From a biomedical perspective, the opportunity is to bring treatment to a patient when the patient cannot yet be brought to treatment,” Associate Professor Do said.
“The long-term goal is targeted, human-supervised intervention in places conventional medical technologies cannot access.”
Dr Vo-Doan said the research demonstrates how cyborg technology can be adapted across different insect platforms.
“Rather than building one robot to do everything, we can harness the natural strengths of different insects and equip them for different missions,” Dr Vo-Doan said.
The larger cockroaches provide greater capacity to carry specialized rescue and medical equipment.
The cockroaches, like the team’s previous cyborg insect models, are anaesthetized during electrode and microchip fitting. They live for as long as other cockroaches once the harnesses are removed.
The team has previously demonstrated cyborg beetles capable of controlled climbing. They have shown they can remotely guide the movement of common darkling beetles using a video game controller.
The beetles are fitted with removable microchip backpacks that use electrodes to stimulate the insect's antenna or hardened forewings.
The programmable controls allow for precise directional guidance without affecting the lifespan of the beetle.
Superintendent Tim Hassiotis, Manager Natural Disaster and Humanitarian at Fire and Rescue NSW, said the technology could extend the reach of rescue teams.
“If cyborg insects can safely enter spaces we can’t, locate casualties and ultimately help deliver emergency care, they could become another valuable tool in the future of urban search and rescue,” Superintendent Hassiotis said.
Dr Vo-Doan said the longer-term vision was to deploy swarms of specialized cyborg insects, with individuals performing complementary roles.
“Some could carry cameras and environmental sensors, while others could carry specialized emergency or medical equipment,” he said.
“Hopefully, within the next 5 to 10 years, we could see cyborg insect rescue teams deployed to help people in real emergencies, provided we have the resources to accelerate the research and field testing.”
Credit: iStock
A North Carolina teen is reportedly critically ill after being infected with a rare “brain-eating” amoeba called Naegleria fowleri, according to health officials.
The case comes barely a week after an 8-year-old Louisiana girl died after contracting the infection.
The North Carolina Department of Health and Human Services announced on August 27 that a teen resident had been infected with the rare amoeba, which is commonly found in freshwater. The teen is critically ill and receiving medical care.
The department said it is not releasing further information to protect the family’s privacy. The source of the infection is under investigation.
“While these infections are very rare, this is an important reminder that this amoeba is present in our state and across the US,” North Carolina State Epidemiologist Dr. Zack Moore said in a statement.
What Happened To The Louisiana Girl?
Eight-year-old Lillian Smart of Ruston died on August 22, just one day after her eighth birthday. She had been hospitalised since August 15 after developing the infection, which was believed to have been acquired while swimming in Lake Claiborne.
The Louisiana Department of Health confirmed the case on August 19 but did not publicly identify the child.
One of the biggest challenges is the speed at which the infection progresses. According to recent CDC data cited in coverage of the Louisiana case, 173 Naegleria fowleri infections were documented in the US between 1937 and 2025, with only four known survivors. This puts the fatality rate at roughly 97%.
What Is Naegleria fowleri?
Naegleria fowleri is an amoeba naturally present in warm freshwater such as ponds, lakes and rivers. It is not found in salt water or properly maintained and chlorinated pools.
The amoeba does not cause illness if swallowed. However, it can be fatal if water containing the amoeba is forced up the nose and reaches the brain. This can happen during activities such as jumping into water, diving and water-skiing.
Symptoms Of Naegleria fowleri Infection
The infection caused by N. fowleri, also called primary amebic meningoencephalitis (PAM), starts with symptoms including:
The infection can then progress to:
These rare infections usually occur when it is hot for prolonged periods, leading to higher water temperatures and lower water levels. Naegleria fowleri grows best at higher temperatures, up to 115°F.
How To Stay Safe?
While there is no way to eliminate the amoeba from the environment, some safety measures can reduce the risk:
Credit: AP Photos
Norway's King Harald V died on Friday at an Oslo hospital where he was undergoing treatment for a rare blood disorder. He was 89.
“King Harald passed away peacefully at Oslo University Hospital on Friday 28 August, 0635 (local time, 0435 GMT),” the Royal Palace said on its website.
Harald, who was Europe's oldest living monarch, had been hospitalized on August 17. He was initially being treated for complications related to hemolytic anemia — a blood condition in which red blood cells are destroyed faster than the body can replace them. He later developed an infection.
Harald's condition worsened in recent days after he was admitted to hospital with fluid accumulation in the body linked to a blood disorder. He subsequently developed an infection.
Family members were called to his bedside on Thursday as his condition deteriorated at Oslo University Hospital.
Following his death, the royal flag was flown at half-mast on the palace roof.
Harald had faced several medical setbacks in recent years. He underwent heart surgeries in 2005 and 2020 and was hospitalised multiple times for infections.
According to Johns Hopkins, haemolytic anaemia is a disorder in which red blood cells are destroyed faster than they can be produced. The destruction of red blood cells is known as haemolysis.
Red blood cells normally carry oxygen from the lungs to the rest of the body. When they are destroyed prematurely and faster than the bone marrow can replace them, the number of circulating red blood cells falls.
This can reduce the amount of oxygen delivered to tissues and cause symptoms such as fatigue, weakness and shortness of breath.
Symptoms can vary from person to person and may include:
These symptoms can also occur with other blood conditions or health problems. A healthcare professional should be consulted for diagnosis.
Diagnosis may involve tests such as:
Treatment depends on the underlying cause and may include:
In more severe cases, treatment may include surgery to remove the spleen or immunosuppressive therapy to reduce immune-system activity.
Harald leaves behind his wife, Queen Sonja, his son and new King Haakon, daughter Princess Märtha Louise and six grandchildren.
Harald V was the first Norwegian-born prince in 567 years.
Following Harald's death, hundreds of people gathered outside the palace in Oslo to lay flowers, while the government declared nationwide mourning until after his funeral.
Harald's 53-year-old son will become Norway's new king, Haakon VIII, while Haakon's 22-year-old daughter Ingrid Alexandra becomes crown princess.
© 2024 Bennett, Coleman & Company Limited